Proscia: Reflections on KLAS’ US Digital Pathology Report: What it Means to Be a Long-Term Partner
recent articles
From the Proscia blog: Going digital is a huge feat, and something well worth celebrating. But the labs seeing the biggest returns chose a platform that keeps compounding value long after go-live, scaling across departments and teams without...
Agreement includes a license for Owkin AI Scientist, K Pro, for three years. As part of this license, Owkin will develop novel biopharma agents for AstraZeneca, usable through K Pro. This will include capabilities to quickly...
From the Proscia blog: We’ve long said that the next major therapeutic breakthrough may lie in pathology data that already exists. At this year’s AACR Annual Meeting, it became clear the biopharma community is arriving at the same...
Regarding the Roche acquisition of PathAI, from Elizabeth Bourn on LinkedIn: This morning, Roche announced that it had entered into a definitive merger agreement to acquire PathAI for $750M upfront, with up to $300M in additional milestone...
Proscia Honored alongside IQVIA, Medidata, and Thermo Fisher Scientific PHILADELPHIA — May 7, 2026 — Proscia®, a company bringing pathology to the center of precision medicine, has been named a winner in the 10th annual MedTech...
PathAI’s best-in-class Image Management System (IMS) with advanced AI analysis and workflow capabilities will complement Roche's digital pathology portfolio to drive laboratory efficiency Combining Roche’s strong position in...
